Intermountain Healthcare, Sandy, UT
Megan Mullalley, Whitney Mortensen, Phillip Barnette, Bradley Hunter, Terence Duane Rhodes, Derrick S. Haslem, David Michael Gill
Background: Biosimilar medications have increasingly gained regulatory approvals in recent years. Numerous conditions in the fields of hematology, oncology, rheumatology, and endocrinology have a biosimilar treatment option available. Some biosimilar agents can be obtained at a significantly lower cost than reference medications. Methods: Intermountain Healthcare Oncology Pharmacy and Therapeutics (P&T) committee manages and maintains the formulary of accepted drugs. The committee consists of pharmacists, medical oncologists and oncology nurses. Biosimilar medications were approved in place of reference medications for the following: pegfilgrastim, bevacizumab, trastuzumab, and rituximab. Results: Annually, we administer about 6,450 combined doses of pegfilgastrim, bevacizumab, trastuzumab, and rituximab. Assuming 70% conversion from the reference medication to biosimilar agent, transitioning from the above listed reference medications to biosimilar would save an estimated $6.3 million annually (Table). This includes a $1.75 million savings from transitioning to rituximab alone. In addition, transitioning trastuzumab from a single dose vial to multi-dose vials is estimated to save an addition $730,000. Conclusions: Biosimilar agents can reduce the cost of oncology care to patients treated at our institution. We are utilizing biosimilar agents as part of our ongoing mission to decrease the financial toxicity of treatment for patients with cancer.
Reference Medication | Doses Administered Annually | 2021 Savings |
---|---|---|
Pegfilgastrim | 2,650 | $696,000 |
Bevacizumab | 1,500 | $1,700,000 |
Trastuzumab | 1,200 | $1,350,000 |
Rituximab | 1,100 | $2,500,000 |
Total | 6,450 | $6,246,000 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Annual Meeting
First Author: John Albaugh
2022 ASCO Annual Meeting
First Author: Lalan S. Wilfong
2022 ASCO Annual Meeting
First Author: Marina Reed
2023 ASCO Annual Meeting
First Author: Suwicha Limvorasak